Lovastatin is a statin drug used to prevent and treat coronary heart disease and to treat high cholesterol. In the present study, oral disintegrating thin films (ODTs) of lovastatin were designed with a view to enhance patient compliance by solvent casting method. In the solvent casting method, Croscarmellose sodium (CCS) (2, 4 and 6 % w/w), Crospovidone (10 and 15% w/w) as superdisintegrants were used in different concentrations with Gelatin, Poly vinyl alcohol (PVA) as a film forming base for the formulation of oral disintegrating thin films of lovastatin. The prepared formulations of films were evaluated for film thickness measurement, folding endurance study, in-vitro disintegration time, in-vitro drug release pattern and drug content. FTIR spectroscopy used to study drug-polymers interaction. Among all formulations, the formulation (F8) prepared by 4% crospovidone show enhanced drug release (99.27%) and it showed good stability for period of three months. Conclusively, the present study documents the development of a commercially viable formula lovastatin ODTs with rapidity in reducing heart problems.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.